KR20090040631A - Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient - Google Patents

Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient Download PDF

Info

Publication number
KR20090040631A
KR20090040631A KR1020070106083A KR20070106083A KR20090040631A KR 20090040631 A KR20090040631 A KR 20090040631A KR 1020070106083 A KR1020070106083 A KR 1020070106083A KR 20070106083 A KR20070106083 A KR 20070106083A KR 20090040631 A KR20090040631 A KR 20090040631A
Authority
KR
South Korea
Prior art keywords
water extract
dandelion
hot water
composition
cells
Prior art date
Application number
KR1020070106083A
Other languages
Korean (ko)
Other versions
KR101307501B1 (en
Inventor
예성수
최춘연
최일환
송영선
Original Assignee
인제대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교 산학협력단 filed Critical 인제대학교 산학협력단
Priority to KR1020070106083A priority Critical patent/KR101307501B1/en
Publication of KR20090040631A publication Critical patent/KR20090040631A/en
Application granted granted Critical
Publication of KR101307501B1 publication Critical patent/KR101307501B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A composition for preventing or treating immune diseases comprising dandelion(Taraxacum offininale) water extract is provided to suppress the generation of nitrogen oxide (NO) and iNOS(inducible nitrogen oxide synthetase) by accelerating the expression of mRNA(messenger RNA) of heme oxygenase-1(HO-1) and protein and increasing the enzyme activity. A composition for preventing or treating immune diseases comprising dandelion(Taraxacum offininale) water extract as an active ingredient. The dandelion water extract is obtained by heating after mixing organic dandelion powder and water, filtering after decompression, freezing and drying them. The one day dose of the active compound is 0.000001-1 mg/kg, preferably 0.001-500 mg/kg, more preferably 10-300 mg/kg. The immunization disease is acute and chronic infection, acute and chronic bronchitis, osteoarthritis, rheumatoid arthritis, sinusitis, gastroenteritis, colitis, cystitis, urethritis, dermatitis, conjunctivitis, pericarditis, peritonitis, synovitis, pleurisy, tendinitis, cholecystitis, vaginitis or uveitis.

Description

민들레 열수추출물을 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물 {COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASE COMPRISING DANDELION WATER EXTRACT AS AN ACTIVE INGREDIENT}COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASE COMPRISING DANDELION WATER EXTRACT AS AN ACTIVE INGREDIENT}

본 발명은 민들레 열수추출물 (dandelion (Taraxacum offininale) water extract, TOWE)의 신규한 용도에 관한 것으로, 보다 구체적으로는 헴옥시게나제-1의 발현 및 활성을 유도하는 상기 민들레 열수추출물을 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a novel use of dandelion ( Taraxacum offininale ) water extract (TOWE), and more particularly, containing the dandelion hot water extract, which induces the expression and activity of hemeoxygenase-1, as an active ingredient. It relates to a composition for the prevention or treatment of immune diseases.

민들레 (dandelion (Taraxacum offininale))는 안질방이, 무슨들레라고도 불리우며, 들이나 길가에 피는 다년생 초본 식물로 꽃은 4-5월에 피며, 예로부터 어린 잎은 나물과 국거리로 식용해 왔다 (김일혁 및 성환길, 약이 되는 풀과 나무, 중앙대학교 출판부, p332, 1997). 또한, 민들레는 꽃이 피기 전에 전초를 건조한 것을 포공영 (김원, 자원식물학, 경북대학교 출판부, p190, 1987)이라 하며 한방에서는 강장, 해열, 이뇨, 건위, 거담, 해독 등에 이용되어 왔다 (홍석화, 한국의 토 종 101가지, 웅진출판사, 1990, 18). 민들레의 맛과 성질은 쓰고 달며, 차갑다. 전초는 이담 작용이 있으며 위액의 분비를 빠르게 한다. Dandelion ( Taraxacum offininale ) is a perennial herbaceous plant that is called the genus of the Anzalea , which is also called a wildebeest . Flowers bloom in April-May, and young leaves have been edible by herbs and national streets. Sunghwan Kil, Herbal Medicine and Trees, Chung-Ang University Press, p332, 1997). Dandelion is also called pogongyoung (Kim Won, Botanical Botany, Kyungpook National University Press, p190, 1987), and it has been used in tonic, fever, diuresis, dry stomach, expectorant, and detoxification in oriental medicine. 101 native species, Woongjin Press, 1990, 18). Dandelion taste and properties are bitter and sweet. Outpost has an edema and speeds up the secretion of gastric juice.

민들레는 타락사스테롤 (taraxasterol), 콜린, 이눌린 및 펙틴 등의 성분을 함유하고, 뿌리는 타락솔 (taraxol), 타락세롤 (taraxenol), 타락스테롤, 베타아미린, 스티그마스테롤, 콜린, 유기산, 과당, 자당, 포도당, 글루코시드 등을 함유하고, 잎은 루틴, 비올라잔틴, 플라스토퀴논, 비타민 C (50-70 ㎎/100 g) 및 비타민 D (5-9 ㎎/100 g)를 함유하며, 꽃은 알니디올, 루틴 및 플라보잔틴을 함유한다 (동양의학대사전, 경희대학교 출판국, p514, 1999). 특수 성분으로 이눌린, 스테롤, 콜린, 팔미틴, 세로친 등을 많이 함유하고 있으며, 특히 민들레의 리놀산과 콜린 성분은 고혈압, 심장병, 간질환 등 성인병에 효과가 있는 것으로 알려져 있다 (Kim YG et al., Free radical, YeoMoonGak, Seoul, 1997). Dandelion contains ingredients such as taraxasterol, choline, inulin and pectin, and roots are taraxol, taraxenol, taraxolol, betaamiline, stigmasterol, choline, organic acids, fructose , Sucrose, glucose, glucoside and the like, the leaves contain rutin, violaxanthin, plastoquinone, vitamin C (50-70 mg / 100 g) and vitamin D (5-9 mg / 100 g), Flowers contain alnidiol, rutin and flavoxanthin (Oriental Medicine Dictionary, Kyung Hee University Press, p514, 1999). As a special ingredient, it contains a lot of inulin, sterol, choline, palmitine and serine. Especially, dandelion linoleic acid and choline are known to be effective in adult diseases such as hypertension, heart disease and liver disease (Kim YG et al. , Free radical, YeoMoon Gak, Seoul, 1997).

이러한 민들레속 식물의 성분연구로는 서양민들레 뿌리에서 ρ-하이드록시 페닐아세트산 (ρ-hydroxyphenyl-acetic acid), 3,4-다이하이드록시신남산 (3,4-dihydroxycinnamic acid), 멜리스산 (melissic acid), 타락사스테릴아세테이트 (taraxasteryl acetate), 타락솔, 타락세롤, ψ-타락사스테롤 등의 많은 약효성분을 분리한 것이 보고되었다 (황완균 등, 좀민들레의 약효 성분 (Ⅰ) 좀민들레 지상부의 Phenol 성분, 25(3):209-213, 1994; 및 Hans-Willi R and Jai-tung H, Phytochemistry, 24:1557-1562, 1985). 서양에서 민들레는 담즙분비 촉진, 항류마티스, 이뇨 등에 약재로 사용되고 있으며 (Yang KS and Jeon CM, Korean J. Pharmacogn., 27:267-273, 1996), 건조한 민들레의 잎과 뿌리는 커피 대용품으로 애용되는데 (Jeong JY et al., Arch. Pharm. Res., 14:68-72, 1991), 특히 폴리페놀화합물 중 플라보노이드, 루테올린, 신남산, 쿠마린, 타락사스테롤 등의 성분 및 엽록소와 비타민 C가 많이 함유되어 있다 (Williams CA et al., Phytochemistry, 42:121-127, 1996).Component in the study of these plants is in Taraxacum Taraxacum officinale roots ρ - hydroxyphenyl acetic acid (ρ -hydroxyphenyl-acetic acid), 3,4- dimethyl hydroxycinnamic acid (3,4-dihydroxycinnamic acid), pyromellitic seusan (melissic acid), taraxasteryl acetate, taraxol, taraxerol, and ψ -taraxasterol have been reported to have been isolated (Hwanwan, etc.) Phenol component, 25 (3): 209-213, 1994; and Hans-Willi R and Jai-tung H, Phytochemistry , 24: 1557-1562, 1985). In the West, dandelion is used as a medicine for bile secretion, antirheumatic and diuretic (Yang KS and Jeon CM, Korean J. Pharmacogn. , 27: 267-273, 1996). (Jeong JY et al. , Arch. Pharm. Res. , 14: 68-72, 1991), especially chlorophyll and vitamin C, among the polyphenolic compounds such as flavonoids, luteolin, cinnamic acid, coumarin, taraxasterol, etc. (Williams CA et al. , Phytochemistry , 42: 121-127, 1996).

헴옥시게나제 (heme oxygenase, HO)는 항산화반응과 관련하여 최근 그 역할이 중요하게 인식되고 있다. HO는 헴 (heme)을 빌리버딘 (biliverdin)으로 변환시키는 속도-제한 효소로서, 이때 일산화탄소 (CO)와 철 (Fe)이 부수적으로 생성된다. 빌리버딘은 이어서 빌리루빈 (bilirubin)으로 환원되어 여러가지 산화물들을 청소하는데 사용된다. HO는 현재까지 알려진 바로는 3가지의 이성체가 존재하는데 (McCoubrey et al., 1997), 계속 발현되는 HO-2 및 HO-3와는 달리 HO-1은 여러 자극들에 의해 유도되는 효소로서 특히 산화성 스트레스에 의해서 유도되어지는 것으로 알려져 있고 (Tenhumen et al., 1970; 및 Choi and Alam, 1996), 특히 항산화와 항염증과 관련된 보호기능을 수행하는 것으로 알려져 있다 (Otterbein et al., 2000; 및 Lee et al., 2003). Heme oxygenase (HO) has recently been recognized for its role in antioxidant activity. HO is a rate-limiting enzyme that converts heme into biliverdin, where incidental production of carbon monoxide (CO) and iron (Fe) occurs. Biliburdine is then reduced to bilirubin and used to clean various oxides. HO is known to have three isomers (McCoubrey et al. , 1997) . Unlike HO-2 and HO-3, which are still expressed, HO-1 is an enzyme induced by several stimuli, especially oxidative. It is known to be induced by stress (Tenhumen et al. , 1970; and Choi and Alam, 1996), and it is known to perform protective functions, particularly antioxidant and anti-inflammatory (Otterbein et al. , 2000; and Lee). et al. , 2003).

또한, HO의 최종산화물인 빌리루빈은 산화적 스트레스로부터 세포를 보호하며, 최근 연구에 의하면 빌리루빈 이외에 일산화탄소 (CO)도 세포를 보호하는데 관여하는 것으로 생각되고 있다. HO가 결핍된 세포에서는 산화적 스트레스에 의한 세포손상을 더욱 증가시킨다고 하는 보고 (Akihiro et al., 1999)에서 알 수 있듯이 HO는 산화적 스트레스에 대한 면역계의 보호에 특히 중요한 효소이다. In addition, bilirubin, the final oxide of HO, protects cells from oxidative stress, and recent studies suggest that carbon monoxide (CO) in addition to bilirubin is also involved in protecting cells. HO is a particularly important enzyme for the protection of the immune system against oxidative stress, as evidenced by reports of increased cell damage by oxidative stress in HO-deficient cells (Akihiro et al. , 1999).

HO-1의 증가는 박테리아독소인 지질다당류 (lipopolysaccharide, LPS)에 의 해 과잉생성이 유도되는 유도성 일산화질소 합성효소 (inducible nitric oxide synthase, iNOS)를 억제하며, 최근에는 이러한 기전을 활용하여 HO-1 증가를 통한 iNOS 억제를 유도하는 유용한 물질들의 개발이 이루어지고 있다 (Chen TH et al., 2007).Increasing HO-1 inhibits inducible nitric oxide synthase (iNOS), which is overproduced by the bacterial toxin lipopolysaccharide (LPS). Development of useful substances that induce iNOS inhibition through an increase of -1 is underway (Chen TH et al. , 2007).

NO는 각종 세포에 의해 생산되어 이들 세포에 작용하고, 염증 및 자가면역이 중재된 조직의 파괴에 관여하는 다기능 중재자인 것으로 알려져 있다. 상기와 같은 NO는 생체 내에서 일산화질소 합성효소 (nitric oxide synthase, NOS)에 의하여 생성되며, NOS는 지속적으로 생성되는 것 (constitutive NOS, cNOS)과 자극에 의해서 생성이 유도되는 것 (inducible NOS, iNOS)이 존재한다. NO is known to be a multifunctional mediator produced by various cells and acting on these cells and involved in the destruction of tissues mediated by inflammation and autoimmunity. Such NO is produced by nitric oxide synthase (NOS) in vivo, and NOS is continuously produced (constitutive NOS, cNOS) and induced by stimulation (inducible NOS, iNOS) is present.

상기 NOS는 L-아르기닌 (L-arginine)으로부터 NO를 생성시키는 효소로 그 중에서 신경계에 존재하는 nNOS (neuronal NOS) 및 혈관계에 존재하는 eNOS (endothelial NOS)는 체내에서 항상 일정 수준으로 발현되고 있으며, 이들에 의해 소량 생성되는 NO는 신경전달이나 혈관확장을 유도하는 등 정상적인 신체의 항상성 유지에 중요한 역할을 한다. 하지만, iNOS는 각종 사이토카인 (cytokines)이나 외부 자극물질에 의해 유도되어 과량의 NO를 급격히 발생시켜 세포독성이나 각종 염증반응을 일으키는 것으로 알려져 있으며, 특히, 만성 염증은 iNOS 활성의 증가와 밀접한 관련이 있다고 알려져 있다 (Miller M. J. et al., Mediators of inflammation, 4:387-396, 1995; 및 Appleton L. et al., Adv. Pharmacol., 35:27-28, 1996). 또한, iNOS의 유전자 발현은 NF-κB와 AP-1 등의 전자조절인자들에 의하여 조절되며, 평상시에는 거의 발현되지 않다가 면역체계가 활성화될 경우에 급 격히 그러나 한시적으로 발현이 유도되어 단백질이 합성된다고 알려져 있다. The NOS is an enzyme for producing NO from L-arginine, among which nNOS (neuronal NOS) present in the nervous system and eNOS (endothelial NOS) present in the vascular system are always expressed at a constant level in the body. NO produced by them plays an important role in maintaining normal homeostasis, such as inducing neurotransmission and vasodilation. However, iNOS is induced by various cytokines or external stimulants, and it is known to rapidly produce excess NO, causing cytotoxicity and various inflammatory reactions. In particular, chronic inflammation is closely related to the increase of iNOS activity. (Miller MJ et al., Mediators of inflammation , 4: 387-396, 1995; and Appleton L. et al., Adv. Pharmacol. , 35: 27-28, 1996). In addition, gene expression of iNOS is regulated by electronic regulators such as NF-κB and AP-1, which are rarely expressed in normal time, but are rapidly or temporarily expressed when the immune system is activated. It is known to be synthesized.

이러한 NO가 세포내에서 과도하게 발현될 경우, 염증이나 자가면역 질환 등의 면역계 질환을 야기하게 되어 염증 및 자가면역 질환 등을 일으키게 된다. 따라서, NO 생성을 저해하는 활성을 갖는 성분은 NO의 과잉생산에 의해 유발되는 질환인 상기 염증이나 자가면역 질환의 예방 및 치료에 효과적일 것이다.When the NO is excessively expressed in the cell, it causes an immune system disease such as inflammation or autoimmune disease, resulting in inflammation and autoimmune disease. Therefore, a component having an activity that inhibits NO production will be effective in preventing and treating the inflammation or autoimmune disease which is a disease caused by the overproduction of NO.

이에 본 발명자들은 NO의 과잉생산으로 인한 질환을 예방 또는 치료하기 위한 치료제의 개발을 위하여 연구를 거듭하던 중, 민들레의 열수추출물이 HO-1의 mRNA 및 단백질 발현을 촉진시키고 효소 활성을 증가시킴으로써 NO 및 iNOS의 생성을 억제하고 과산화수소에 의한 세포손상을 감소시킬 수 있음을 규명함으로써 본 발명을 완성하였다.Therefore, the present inventors have been conducting research for the development of a therapeutic agent for preventing or treating a disease caused by the overproduction of NO, and the dandelion hot water extract promotes the mRNA and protein expression of HO-1 and increases the enzyme activity. The present invention has been completed by identifying that iNOS can be inhibited and cell damage caused by hydrogen peroxide can be reduced.

본 발명의 목적은 HO-1의 발현 및 활성 유도를 통하여 면역질환을 예방 또는 치료할 수 있는 조성물을 제공하는 데 있다.An object of the present invention to provide a composition that can prevent or treat immune diseases through the induction of the expression and activity of HO-1.

본 발명의 다른 목적은 면역질환을 효과적으로 예방할 수 있는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition that can effectively prevent immune diseases.

상기와 같은 목적을 달성하기 위하여, 본 발명은 민들레 열수추출물을 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물을 제공한다. In order to achieve the above object, the present invention provides a composition for the prevention or treatment of immune diseases containing dandelion hot water extract as an active ingredient.

상기 다른 목적을 달성하기 위하여, 본 발명은 민들레 열수추출물을 포함하는 면역질환의 예방용 식품 조성물을 제공한다.In order to achieve the above another object, the present invention provides a food composition for the prevention of immune diseases comprising dandelion hot water extract.

민들레 열수추출물을 포함하는 본 발명의 조성물은 면역세포 내에서 HO-1의 유전자 발현 및 효소 활성을 증가시킬 수 있으므로, 면역질환의 예방 또는 치료에 효과적으로 이용될 수 있다.Since the composition of the present invention comprising dandelion hot water extract can increase the gene expression and enzyme activity of HO-1 in immune cells, it can be effectively used for the prevention or treatment of immune diseases.

본 발명에 따른 민들레 열수추출물을 유효성분으로 함유하는 약학적 조성물 은 HO-1의 발현 및 효소 활성을 증가시키는 활성을 가지고 있을 뿐 아니라, LPS에 의해 과잉생산이 유도되는 NO 및 iNOS의 생성을 억제하고, 과산화수소에 의해 유도되는 세포손상을 막아주며, 또한 상기 민들레 열수추출물은 세포의 생존율에 영향을 주지 않아 부작용을 나타내지 않으며, 식용 식물에서 유래된 천연물질이므로 안전하다. The pharmaceutical composition containing dandelion hot water extract according to the present invention as an active ingredient not only has the activity of increasing the expression and enzyme activity of HO-1, but also inhibits the production of NO and iNOS induced by overproduction by LPS. In addition, it prevents cell damage induced by hydrogen peroxide, and the dandelion hot water extract does not affect the survival rate of the cells and does not show side effects, and is safe because it is a natural substance derived from an edible plant.

본 발명의 일실시예에서는 민들레 열수추출물이 HO-1의 발현을 유도하는지 여부를 확인하기 위해 마우스의 대식세포주인 RAW 264.7 세포주에 민들레 열수추출물을 처리하고 배양한 후, 세포로부터 단백질을 분리하고, HO-1 단백질에 대하여 효소 반응을 실시하였다. 그 결과, 민들레 열수추출물이 HO-1의 효소 활성을 증가시키는 것을 확인하였으며, 민들레 열수추출물에 의한 HO-1 효소 활성의 증가는 기존의 HO-1 활성 증가제인 hemin의 효과에 버금감을 알 수 있었다 (도 1 참조).In one embodiment of the present invention, to determine whether the dandelion hot water extract induces the expression of HO-1 treated with dandelion hot water extract in the macrophage line RAW 264.7 cell line of the mouse and cultured, and then isolate the protein from the cells, An enzyme reaction was performed on the HO-1 protein. As a result, it was confirmed that dandelion hot water extract increased the enzyme activity of HO-1, and the increase of HO-1 enzyme activity by dandelion hot water extract was comparable to the effect of hemin, which is a conventional HO-1 activity increasing agent. (See Figure 1).

본 발명의 또 다른 실시예에서는 민들레 열수추출물을 단독으로 또는 염증반응과 같은 면역반응을 유도하는 박테리아 독소인 LPS (lipopolysaccharide)와 혼합 처리하고 배양한 후, 세포로부터 단백질을 분리하고, HO-1 단백질에 대한 항체를 사용하여 웨스턴 블럿 (western blot)을 실시하였다. 그 결과, 민들레 열수추출물이 HO-1의 단백질 생성의 증가를 유도하는 것을 확인하였다 (도 2 참조). 따라서, 민들레 열수추출물에 의한 HO-1 효소 활성의 증가는 HO-1 단백질 발현 증가 효과에 기인한 것임을 알 수 있다.In another embodiment of the present invention, the dandelion hot water extract alone or mixed and cultured with a bacterial toxin LPS (lipopolysaccharide), which induces an immune response such as an inflammatory reaction, and then cultures the protein from the cells, and HO-1 protein Western blots were performed using antibodies against. As a result, the dandelion hot water extract was confirmed to induce an increase in the protein production of HO-1 (see Fig. 2). Therefore, it can be seen that the increase of HO-1 enzyme activity by dandelion hot water extract is due to the effect of increasing HO-1 protein expression.

본 발명의 또 다른 실시예에서는 민들레 열수추출물 및 LPS를 처리한 세포를 배양 후, 세포로부터 RNA를 분리하여 역전사-중합효소반응 (reverse transcription-polymerase chain reaction) 분석을 실시하였다. 그 결과, 민들레 열수추출물이 mRNA 수준에서 HO-1의 유전자 발현을 유도하는 것을 확인하였다 (도 3 참조).In another embodiment of the present invention, after culturing the dandelion hot water extract and LPS-treated cells, RNA was isolated from the cells and subjected to reverse transcription-polymerase chain reaction analysis. As a result, it was confirmed that the dandelion hot water extract induces gene expression of HO-1 at the mRNA level (see FIG. 3).

또한, 본 발명의 또 다른 실시예에서는 HO-1 발현 유도에 의한 iNOS 생성 억제 여부를 확인하기 위하여 민들레 열수추출물 및 LPS를 처리한 세포를 배양한 후, 세포로부터 단백질을 분리하고, iNOS 단백질에 대한 항체를 사용하여 웨스턴 블럿 (western blot)을 실시하였다. 그 결과, 민들레 열수추출물이 단백질 수준에서 iNOS의 합성을 억제하는 것을 확인하였다 (도 4 참조). 따라서, 민들레 열수추출물에 의한 HO-1의 발현 유도는 iNOS 효소 발현 억제 효과와 관련이 있음을 알 수 있다.In addition, in another embodiment of the present invention, after culturing the cells treated with dandelion hot water extract and LPS in order to determine whether inhibition of iNOS production by HO-1 expression induction, and to separate the protein from the cells, for the iNOS protein Western blots were performed using the antibodies. As a result, it was confirmed that the dandelion hot water extract inhibits the synthesis of iNOS at the protein level (see FIG. 4). Therefore, it can be seen that the induction of HO-1 expression by dandelion hot water extract is related to the iNOS enzyme expression inhibitory effect.

또한, 세포가 배양된 배지를 회수하여 세포가 생성하는 아질산염 (nitrite)의 양을 측정하여 NO 생성의 정도를 측정한 결과, 민들레 열수추출물이 농도-의존적으로 대식세포에서의 NO의 생성을 효과적으로 억제하였고, 이 때 세포의 생존율에는 변화가 없음을 확인하였다 (도 5 및 6 참조).In addition, as a result of recovering the medium in which the cells were cultured and measuring the amount of nitrite produced by the cells, the degree of NO production was measured. As a result, dandelion hot water extract effectively inhibited NO production in macrophages in a concentration-dependent manner. At this time, it was confirmed that there was no change in viability of the cells (see FIGS. 5 and 6).

본 발명의 또 다른 실시예에서는 세포손상을 유도하는 산화 스트레스로서 과산화수소를 처리하였을 때 민들레 열수추출물의 세포 보호 효과를 확인하기 위하여 민들레 열수추출물 및 과산화수소를 처리하고 배양한 후, 세포의 생존율을 측정하였다. 그 결과, 과산화수소에 의한 세포 생존율의 감소가 민들레 열수추출물에 의하여 회복되는 것을 확인하였다 (도 7 참조), 이로부터 민들레 열수추출물은 과산 화수소와 같은 산화적 스트레스에 의한 세포 손상을 막아준다는 것을 알 수 있었다.In another embodiment of the present invention, in order to confirm the cellular protective effect of dandelion hot water extract when treated with hydrogen peroxide as oxidative stress inducing cell damage, after treating and cultivating dandelion hot water extract and hydrogen peroxide, the survival rate of the cells was measured. . As a result, it was confirmed that the decrease in cell viability caused by hydrogen peroxide was recovered by the dandelion hot water extract (see FIG. 7). From this, it was found that the dandelion hot water extract prevented cell damage caused by oxidative stress such as hydrogen peroxide. there was.

따라서, 상기 민들레 열수추출물을 유효성분으로 포함하는 본 발명의 조성물은 HO-1의 발현 및 활성을 유도할 수 있으므로, 면역질환의 치료제로써 사용될 수 있다.Therefore, the composition of the present invention comprising the dandelion hot water extract as an active ingredient can induce the expression and activity of HO-1, can be used as a therapeutic agent for immune diseases.

상기 면역질환의 대표적인 예로 염증성 질환을 들 수 있는데, 염증은 열, 홍조, 팽윤, 통증 및 기능 상실로 나타난다. 염증의 원인은 미생물 감염 (세균 및 진균 감염), 물리적 인자 (화상, 조사 및 외상), 화학적 제제 (독소 및 유발 물질), 조직 괴사 및 각종 유형의 면역학적 반응과 같은 인자들을 포함하며, 특히 NO를 발생시키는 효소인 NOS와 프로스타글란딘의 생합성과 관련된 효소들이 염증반응을 매개하는데 있어서 중요한 역할을 하고 있는 것으로 알려져 있고, 면역 반응 및 염증 반응에서 생산된 다수의 반응성 생성물 중 하나인 NO는 특히 만성 염증에 있어서 비특이적인 조직 파괴를 유발하는 것으로 알려져 있다.Representative examples of the immune diseases include inflammatory diseases, which are manifested by fever, flushing, swelling, pain and loss of function. Causes of inflammation include factors such as microbial infections (bacterial and fungal infections), physical factors (burns, irradiation and trauma), chemical agents (toxins and triggers), tissue necrosis and various types of immunological reactions, especially NO Enzymes related to the biosynthesis of NOS and prostaglandins, which are enzymes that produce N, are known to play an important role in mediating the inflammatory response, and NO, one of the many reactive products produced in immune and inflammatory responses, is particularly responsible for chronic inflammation. It is known to cause nonspecific tissue destruction.

본 발명의 민들레 열수추출물이 적용될 수 있는 NO의 과잉생산에 의한 질환은, 이에 한정되지는 않으나, 예를 들면, 급성 및 만성 감염, 급성 및 만성 기관지염, 골관절염, 류마티스 관절염, 정맥동염, 위장염, 대장염, 방광염, 요도염, 피부염, 결막염, 심막염, 복막염, 활막염, 흉막염, 건염, 담낭염, 질염 및 포도막염 등을 포함한다.Diseases caused by the overproduction of NO to which the dandelion hot water extract of the present invention can be applied are, but are not limited to, for example, acute and chronic infections, acute and chronic bronchitis, osteoarthritis, rheumatoid arthritis, sinusitis, gastroenteritis, colitis Cystitis, urethritis, dermatitis, conjunctivitis, pericarditis, peritonitis, synovitis, pleurisy, tendonitis, cholecystitis, vaginitis and uveitis.

본 발명에서 사용가능한 민들레 열수추출물은 자연으로부터 얻거나 상업적으로 구입한 민들레, 예를 들어 경남의령 소재 민들레식품으로부터 유기농 민들레분 말을 이용하여 추출물을 조제할 수 있다. 상기 추출물은 공지된 방법을 사용하여 추출할 수 있으며, 이를 감압여과한 후 동결건조하여 사용하는 것이 바람직하다.Dandelion hot water extract can be used in the present invention can be prepared by using an organic dandelion powder from dandelion obtained from nature or commercially purchased dandelion, for example, dandelion foods of Gyeongnam. The extract can be extracted using a known method, it is preferable to use after filtration and freeze-dried under reduced pressure.

본 발명의 약학적 조성물에서 본 발명의 민들레 열수추출물은 단독으로 사용되거나 또는 선택된 투여 경로에 따라 하나 이상의 약학적으로 허용되는 담체와 배합하여 제형화될 수 있다.In the pharmaceutical composition of the present invention, the dandelion hot water extract of the present invention may be used alone or formulated in combination with one or more pharmaceutically acceptable carriers according to the selected route of administration.

본 발명의 약학적 조성물의 투여 경로는 경구 투여 또는 비경구 투여가 모두 가능하며, 비경구적인 투여 경로로는 이에 한정되지는 않으나, 피하 내, 정맥 내, 근육 내, 또는 복강 내 투여될 수 있다.The route of administration of the pharmaceutical composition of the present invention can be administered orally or parenterally, and the parenteral route of administration is not limited thereto, but may be administered subcutaneously, intravenously, intramuscularly, or intraperitoneally. .

본 발명의 약학적 조성물의 경구 투여를 위해서는 캡슐, 정제, 환제, 과립제 및 산제와 같은 고체 형태 또는 엘릭시스 시럽 및 현탁제와 같은 액체 형태로 제형화될 수 있다. 경구 투여를 위해 고체 형태로 제형화하는 경우에는 적합한 담체로서 당분야에 공지된 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등을 사용할 수 있다. 예를 들어, 본 발명의 약학적 조성물을 캡슐로 제형화하기 위해서는 유당, 전분, 셀룰로오즈 유도체, 마그네슘 스테아레이트, 스테아린산과 같은 담체를 사용할 수 있다. 또한, 희석제를 사용하여 압착된 정제의 형태로 제조할 수 있으며 상기 정제와 캡슐은 모두 당분야에 공지된 방법에 따라 서방성으로 제조하여 수시간에 걸쳐 약제가 연속 방출되도록 할 수 있다. 또한, 압착된 정제는 당 피복 또는 필름 피복을 시킬 수 있다. 경구 투여를 위해 액체 형태로 제형화하는 경우에는 적합한 담체로서 당분야에 공지된 현탁제, 유제, 시럽제, 희석제, 습윤제, 감미제, 방향제, 보존제 등을 사용할 수 있다.For oral administration of the pharmaceutical compositions of the present invention may be formulated in solid forms such as capsules, tablets, pills, granules and powders or in liquid form such as elixis syrups and suspensions. When formulated in solid form for oral administration, fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like known in the art can be used as suitable carriers. For example, to formulate the pharmaceutical composition of the present invention in capsules, carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid can be used. In addition, it can be prepared in the form of compressed tablets using a diluent and both the tablets and capsules can be prepared in a sustained release according to methods known in the art to allow the continuous release of the drug over several hours. In addition, the compressed tablets may have a sugar coating or a film coating. When formulated in liquid form for oral administration, suspending agents, emulsions, syrups, diluents, wetting agents, sweetening agents, fragrances, preservatives and the like known in the art can be used as suitable carriers.

본 발명의 약학적 조성물의 비경구 투여를 위해서는 앰플 또는 바이알 단위의 주사제 형태가 바람직하다. 주사제로 제형화하는 경우의 적합한 담체로는 당분야에 공지된 안정제, 완충물질 및 보존제 등을 사용할 수 있고, 적합한 안정제로는 나트륨 비설파이트, 나트륨 설파이트 및 아스코르브산 등이 있으며, 보존제로는 염화벤즈알코늄, 메틸 또는 프로필-파라벤 및 클로로부탄올 등이 있다.For parenteral administration of the pharmaceutical compositions of the invention, the form of injectables in ampoules or vials is preferred. Suitable carriers when formulated as injectables include stabilizers, buffers and preservatives known in the art, and suitable stabilizers include sodium bisulfite, sodium sulfite and ascorbic acid, and the like. Benzalkonium, methyl or propyl-paraben and chlorobutanol.

본 발명의 약학적 조성물의 활성 화합물의 통상적인 1일 투여량은 0.000001 내지 1 ㎎/㎏ 체중, 바람직하게는 0.001 내지 500 ㎎/㎏ 체중, 바람직하게는 10 내지 300 ㎎/㎏ 체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 유효성분의 실제 투여량은 의사의 의학적 판단 하에 환자의 연령, 건강정도, 체중, 배설율, 식이, 질병 중증도, 사용된 화합물의 활성, 성별, 투여 시간, 투여 경로, 치료 기간 및 치료 횟수 등에 따라 결정되어야 하는 것으로 이해되어야 하며, 따라서, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.Typical daily dosages of the active compounds of the pharmaceutical compositions of the invention may range from 0.000001 to 1 mg / kg body weight, preferably from 0.001 to 500 mg / kg body weight, preferably from 10 to 300 mg / kg body weight. It can be administered once or divided into several times. However, the actual dosage of the active ingredient is determined by the medical judgment of the patient, including age, health, weight, excretion, diet, severity, activity of the compound used, sex, time of administration, route of administration, duration of treatment and frequency of treatment. It is to be understood that such determinations should be made in accordance with the foregoing, and therefore the above dosages do not limit the scope of the invention in any way.

본 발명의 민들레 열수추출물은 천역약재로서 안전성이 확보되어 있으며, 마우스에 복강내투여시의 50% 치사량 (LD50)은 적어도 추출물 28 g/㎏ 이상인 안전한 물질이다 (K. Schㆌtz et al., Journal of Ethnopharmacology, 107:313-323, 2006). Dandelion hot water extract of the present invention is secured as a natural drug, 50% lethal dose (LD 50 ) of the intraperitoneal administration to mice is a safe substance of at least 28 g / kg extract (K. Sch ㆌ tz et al. , Journal of Ethnopharmacology , 107: 313-323, 2006).

또한, 본 발명의 상기 민들레 열수추출물은 각종 면역질환의 예방 등의 목적으로 식품 또는 음료에 첨가될 수 있다.In addition, the dandelion hot water extract of the present invention may be added to food or beverage for the purpose of prevention of various immune diseases.

본 발명의 건강음료는 필수성분으로서 상기 민들레 열수추출물을 함유하는 것 외에는 액체성분에 특별한 제한점은 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 향미제로서는 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어, 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 예는 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 수크로스 등; 및 다당류, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리쓰리톨 등의 당알콜이다. The health beverage of the present invention has no particular limitation on the liquid component except for containing the dandelion hot water extract as an essential ingredient, and may contain various flavors or natural carbohydrates as additional components, as in general beverages. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. Examples of the natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol.

상기 외에 본 발명의 식품 또는 음료 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the food or beverage composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, and preservatives. , Glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.

건강 보조식품 개발을 위하여 본 발명의 상기 민들레 열수추출물을 첨가할 수 있는 식품으로는, 예를 들어 각종, 식품류, 음료류, 껌류, 미타민 복합제 등이 있다. Examples of foods to which the dandelion hot water extract of the present invention may be added for the development of dietary supplements include various foods, beverages, gums, mitamine complexes and the like.

이하, 본 발명을 하기 실시예에 의거하여 더 상세하게 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 한정하지는 않는다. Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are not intended to limit the invention only.

하기 실시예에서 도면상에 표시된 * 및 **는 통계분석결과를 나타내는 것으 로서, 민들레 열수추출물을 처리하지 않은 군 (도면에서 처리 농도가 0인 군)에 대하여 *는 p<0.05를 나타내며, **는 p<0.01을 나타낸다 (통계분석은 Dunnett's two-tailed t-test를 수행한 것이다). In the following examples, * and ** indicated on the drawings indicate statistical analysis results. For the group not treated with the dandelion hot water extract (the group having 0 concentration in the figure), * indicates p <0.05. * Indicates p <0.01 (statistical analysis performed Dunnett's two-tailed t-test).

제조예 1: 민들레 열수추출물의 제조 Preparation Example 1 Preparation of Dandelion Hot Water Extract

본 발명의 민들레 열수추출물을 제조하기 위하여, 경남의령 소재 민들레식품으로부터 유기농 민들레 분말을 공급받아 분말 시료 1 kg에 10배의 증류수를 가한 다음, 100±5℃에서 환류냉각관을 부착하여 4시간 동안 추출하고 여과지 (Whatman paper No. 4)를 사용하여 감압여과한 후 동결 건조하였다. 이때, 민들레 추출물의 회수율은 22.5%였다.In order to manufacture the dandelion hot water extract of the present invention, the organic dandelion powder supplied from dandelion food of Gyeongnam Ryeongyeong added 10 times distilled water to 1 kg of the powder sample, and then attached to the reflux cooling tube at 100 ± 5 ℃ for 4 hours Extraction, filtration under reduced pressure using a filter paper (Whatman paper No. 4), and freeze-dried. At this time, the recovery rate of the dandelion extract was 22.5%.

실시예 1: 민들레 열수추출물에 의한 HO-1 효소 활성 증가 유도 Example 1 Induction of HO-1 Enzyme Activity Increase by Dandelion Hot Water Extract

본 발명의 민들레 열수추출물이 HO-1의 효소 활성을 유도하는지 확인하기 위하여, 마우스 대식세포주인 RAW 264.7 세포 (American Type Culture Collection, Manassas, VA, USA)를 사용하여 민들레 열수추출물의 효과를 측정하였다. In order to confirm whether the dandelion hot water extract of the present invention induces the enzyme activity of HO-1, the effect of dandelion hot water extract was measured using RAW 264.7 cells (American Type Culture Collection, Manassas, VA, USA), a mouse macrophage line. .

구체적으로, RAW 264.7 세포를 페니실린 100 유닛/㎖, 스트렙토마이신 100 ㎍/㎖ 및 우태아혈청 (fetal bovine serum) 5%를 포함하는 RPMI 1640 배지 (이하, 편의상 'RPMI 배지'라 함)에서 1×106 세포/㎖의 농도로 현탁하여 배양접시에 깐 다음, 5% CO2 배양기에서 37℃의 조건으로 배양하였다. 상기 RAW264.7 세포를 배양하 면서 민들레 열수추출물을 각각 100, 500 및 1,000 ㎍/ml의 농도로 처리하고 18시간 동안 배양하였다. 대조군으로는 기존의 HO-1 유도물질로 알려진 헤민 (hemin) 100 μM을 처리한 군을 사용하였다. 이후, 세포를 회수하여 HO-1 효소 반응계를 이용하여 효소 반응을 시키고 그 산물인 빌리루빈의 흡광도를 측정하여 HO-1 효소 활성도를 측정하여 그 결과를 도 1에 나타내었다. 또한, 회수된 세포는 세포생존율 측정에도 이용하였으며, 세포생존율은 MTT 분석법에 따라 측정하여 그 결과를 도 6에 나타내었다.Specifically, RAW 264.7 cells were treated with 1 × in RPMI 1640 medium (hereinafter referred to as 'RPMI medium' for convenience) containing 100 units / ml penicillin, 100 μg / ml streptomycin and 5% fetal bovine serum. The cells were suspended in a concentration of 10 6 cells / ml, placed in a culture dish, and incubated at 37 ° C. in a 5% CO 2 incubator. While culturing the RAW264.7 cells, the dandelion hot water extract was treated at concentrations of 100, 500 and 1,000 ㎍ / ml, respectively, and incubated for 18 hours. As a control group, a group treated with 100 μM of hemin known as a HO-1 inducer was used. Thereafter, the cells were collected and subjected to enzymatic reaction using a HO-1 enzyme reaction system. The absorbance of the product, bilirubin, was measured to measure HO-1 enzyme activity, and the results are shown in FIG. 1. In addition, the recovered cells were also used for measuring cell viability, and cell viability was measured according to the MTT assay, and the results are shown in FIG. 6.

도 1 및 6에 나타난 바와 같이, 민들레 열수추출물을 처리한 군에서는 그 투여량이 증가함에 따라 HO-1 HO-1 효소의 활성이 증가하였으며, 그 수준은 헤민을 처리한 대조군의 경우에 비견될 수 있었다. 또한, 도 5에 나타난 바와 같이, 이때의 세포생존율에는 전혀 변화가 없음을 확인하였다.As shown in Figures 1 and 6, in the group treated with dandelion hot water extract, the activity of HO-1 HO-1 enzyme increased with increasing dose, and the level could be comparable to that of the control group treated with hemin. there was. In addition, as shown in Figure 5, it was confirmed that there is no change in the cell viability at this time.

실시예 2: 민들레 열수추출물에 의한 HO-1 발현 유도 측정 Example 2 Measurement of Induction of HO-1 Expression by Dandelion Hot Water Extract

<2-1> 웨스턴 블럿을 이용한 HO-1 발현 유도 측정 <2-1> Measurement of HO-1 Induction by Western Blot

본 발명의 민들레 열수추출물이 HO-1의 발현을 유도하는지 여부를 웨스턴 블럿을 통해 확인하였다.Whether the dandelion hot water extract of the present invention induces the expression of HO-1 was confirmed by Western blot.

구체적으로, RAW264.7 세포를 RPMI 배지를 이용하여 1×106 세포/㎖의 농도로 현탁하여 배양접시에 깐 다음, 5% CO2 배양기에서 37℃의 조건으로 배양하면서 민들레 열수추출물을 100, 500 및 1,000 ㎍/ml의 농도로 처리하여 24시간 동안 배양하였다. 활성화된 세포에서의 영향 측정을 위해서는 민들레 열수추출물 처리 1시간 후에 LPS 200 ng/㎖을 처리한 후 다시 24시간 동안 배양하였다. 이후, 세포를 회수하여 항-마우스 HO-1 항체 (Santa Cruz Biotechnology 사, 미국; 희석비율 1:1,000)를 사용하여 웨스턴 블럿을 수행하였고, 시료 내의 다른 단백질에는 변화가 없음을 보여주기 위한 대조군으로서 항-마우스 베타-액틴 항체 (Cell Signaling Technology 사, 미국; 희석비율 1:1,000)를 사용하였으며, 그 결과를 도 2에 나타내었다.Specifically, the RAW264.7 cells were suspended in a concentration of 1 × 10 6 cells / ml using RPMI medium and placed in a culture dish, followed by culturing at 37 ° C. in a 5% CO 2 incubator to obtain 100, 100% of dandelion hot water extract. The cells were incubated for 24 hours by treatment at concentrations of 500 and 1,000 μg / ml. In order to measure the effect on the activated cells, after treatment with LPS 200 ng / 1 hour after dandelion hot water extract treatment was incubated for another 24 hours. The cells were then harvested and subjected to Western blot using an anti-mouse HO-1 antibody (Santa Cruz Biotechnology, USA; Dilution Ratio 1: 1,000), as a control to show no change in other proteins in the sample. An anti-mouse beta-actin antibody (Cell Signaling Technology, USA; dilution ratio 1: 1,000) was used and the results are shown in FIG. 2.

도 2에 나타난 바와 같이, LPS 처리 여부와 상관없이 민들레 열수추출물의 처리는 HO-1 단백질 합성을 증가시켰으며, 투여한 민들레 열수추출물의 양이 증가할수록 HO-1 단백질 합성이 더욱 증가되는 것을 확인할 수 있었다. As shown in Figure 2, whether or not LPS treatment, dandelion hot water extract treatment increased HO-1 protein synthesis, and as the amount of dandelion hot water extract administered increased HO-1 protein synthesis was confirmed to further increase Could.

<2-2> 역전사-중합효소반응 (RT-PCR)을 이용한 HO-1 합성 증가 측정<2-2> Measurement of HO-1 Synthesis Increase by Reverse Transcription-Polymerase Reaction (RT-PCR)

본 발명의 민들레 열수추출물에 의한 HO-1의 합성 증가를 mRNA 수준에서 확인하기 위하여, RT-PCR을 수행하였다.In order to confirm the increase in the synthesis of HO-1 by the dandelion hot water extract of the present invention at the mRNA level, RT-PCR was performed.

구체적으로, 상기 <2-1>과 동일한 방법으로 세포를 배양한 후, 민들레 열수추출물을 100, 500 및 1,000 ㎍/ml의 농도로 처리한 다음, 1시간 후에 세포를 활성화시키기 위하여 LPS를 처리하고 6시간 동안 배양하였다. 이후, 세포를 회수하여 RNA를 분리한 다음, HO-1 유전자에 대한 RT-PCR을 수행하였고, 시료 내의 다른 유전자에는 변화가 없음을 보여주기 위한 대조군으로서 베타-액틴 유전자에 대한 RT- PCR도 수행하였다. RT-PCR의 반응산물로 1% 아가로즈겔 전기영동을 수행하여 그 결과를 도 3에 나타내었다.Specifically, after culturing the cells in the same manner as in <2-1>, and treated with dandelion hot water extract at the concentration of 100, 500 and 1,000 ㎍ / ml, and then treated with LPS to activate the cells after 1 hour Incubated for 6 hours. Thereafter, the cells were recovered to separate RNA, and then RT-PCR was performed on the HO-1 gene. RT-PCR was also performed on the beta-actin gene as a control to show that there was no change in other genes in the sample. It was. 1% agarose gel electrophoresis was performed with the reaction product of RT-PCR, and the results are shown in FIG. 3.

도 3에 나타난 바와 같이, 본 발명의 민들레 열수추출물을 농도별로 처리한 군은 농도 의존적으로 HO-1의 mRNA의 양이 증가함을 확인할 수 있었다. As shown in Figure 3, the group treated with the dandelion hot water extract of the present invention was found to increase the amount of mRNA of HO-1 in a concentration-dependent manner.

실시예 3: 민들레 열수추출물에 의한 iNOS 억제 활성 측정 Example 3 Measurement of iNOS Inhibitory Activity by Dandelion Hot Water Extract

본 발명의 민들레 열수추출물이 iNOS의 발현을 저해하는 활성을 갖는지 여부를 웨스턴 블럿을 통해 확인하였다.Whether the dandelion hot water extract of the present invention has an activity of inhibiting the expression of iNOS was confirmed by Western blot.

구체적으로, RAW264.7 세포를 RPMI 배지를 이용하여 1×106 세포/㎖의 농도로 현탁하여 배양접시에 깐 다음, 5% CO2 배양기에서 37℃의 조건으로 배양하면서 민들레 열수추출물을 100, 500 및 1,000 ㎍/ml의 농도로 처리하고, 1시간 후에 세포를 활성화시키기 위하여 LPS 200 ng/㎖을 처리한 후 다시 24시간 동안 배양하였다. 대조군으로는 LPS를 처리하지 않은 군 및 LPS만 처리한 군을 사용하였다. 이후, 세포를 회수하여 항-마우스 iNOS 항체 (Santa Cruz Biotechnology 사, 미국; 희석비율 1:1,000)를 사용하여 웨스턴 블럿을 수행하였고, 시료 내의 다른 단백질에는 변화가 없음을 보여주기 위한 대조군으로서 항-마우스 베타-액틴 항체 (Cell Signaling Technology 사, 미국; 희석비율 1:1,000)를 사용하였으며, 그 결과를 도 4에 나타내었다.Specifically, the RAW264.7 cells were suspended in a concentration of 1 × 10 6 cells / ml using RPMI medium and placed in a culture dish, followed by culturing at 37 ° C. in a 5% CO 2 incubator to obtain 100, 100% of dandelion hot water extract. The cells were treated at concentrations of 500 and 1,000 μg / ml, and treated with 200 ng / ml of LPS to activate the cells after 1 hour and then incubated for another 24 hours. As a control group, a group not treated with LPS and a group treated with only LPS were used. Cells were then harvested and subjected to Western blot using an anti-mouse iNOS antibody (Santa Cruz Biotechnology, USA; Dilution Ratio 1: 1,000), and as a control to show no change in other proteins in the sample. Mouse beta-actin antibody (Cell Signaling Technology, USA; dilution ratio 1: 1,000) was used, the results are shown in FIG.

도 4에 나타난 바와 같이, LPS만 처리한 군에서는 iNOS 단백질 합성이 LPS를 처리하지 않은 군에 비해 월등히 증가되었음을 확인할 수 있었고, 민들레 열수추출물을 투여한 군에서는 민들레 열수추출물의 양이 증가할수록 iNOS 단백질 합성이 더욱 억제되는 것을 확인할 수 있었다.As shown in FIG. 4, iNOS protein synthesis was significantly increased in the LPS-treated group compared with the LPS-treated group, and the iNOS protein was increased as the amount of dandelion hot-water extract increased. It was confirmed that the synthesis was further suppressed.

또한, 이때 민들레 열수추출물의 처리 시 HO-1 단백질은 농도-의존적으로 증가하는 결과를 보였으므로, 민들레 열수추출물의 iNOS 생성 억제 효과는 HO-1의 증가와 관련이 있음을 알 수 있었다.In addition, since the HO-1 protein concentration-dependently increased when the dandelion hydrothermal extract was treated, it was found that the inhibitory effect of iNOS production of the dandelion hydrothermal extract was related to the increase of HO-1.

실시예 4: 민들레 열수추출물에 의한 NO 생성 억제 활성 및 세포생존율 측정 Example 4 Measurement of NO Production Inhibition Activity and Cell Viability by Dandelion Hot Water Extract

본 발명의 민들레 열수추출물이 NO의 생성을 억제하는지 확인하기 위하여, 비활성화시에는 NO 생성 수준이 매우 낮으나, LPS로 활성화시킬 때 NO 생성이 유도된다고 알려져 있는 마우스 대식세포주인 RAW 264.7 세포를 사용하여 민들레 열수추출물의 효과를 측정하였다. To confirm whether the dandelion hot water extract of the present invention inhibits NO production, the dandelion using RAW 264.7 cells, a mouse macrophage line known to induce NO production at the time of inactivation, but is activated when activated by LPS. The effect of hot water extract was measured.

구체적으로, RAW264.7 세포를 RPMI 배지를 이용하여 1×106 세포/㎖의 농도로 현탁하여 배양접시에 깐 다음, 5% CO2 배양기에서 37℃의 조건으로 배양하면서 민들레 열수추출물을 100, 500 및 1,000 μg/ml의 농도로 처리하고, 1시간 후에 세포를 활성화시키기 위하여 LPS 200 ng/㎖을 처리한 후 다시 24시간 동안 배양하였다. 대조군으로는 LPS를 처리하지 않은 군 및 LPS만 처리한 군을 사용하였다. 이후, 세포 배양액을 회수하여 NO의 양을 그리에스 (Griess) 반응을 이용하여 측정하여 그 결과를 도 5에 나타내었다. 또한, 세포는 회수하여 세포생존율 측정에 이용 하였으며, 세포생존율은 MTT 분석법에 따라 측정하여 그 결과를 도 5 및 6에 나타내었다.Specifically, the RAW264.7 cells were suspended in a concentration of 1 × 10 6 cells / ml using RPMI medium and placed in a culture dish, followed by culturing at 37 ° C. in a 5% CO 2 incubator to obtain 100, 100% of dandelion hot water extract. The cells were treated at concentrations of 500 and 1,000 μg / ml, and treated with 200 ng / ml of LPS to activate cells after 1 hour and then incubated for another 24 hours. As a control group, a group not treated with LPS and a group treated with only LPS were used. Thereafter, the cell culture was recovered and the amount of NO was measured using a Gries's reaction, and the results are shown in FIG. 5. In addition, cells were recovered and used for measuring cell viability, and cell viability was measured by MTT assay and the results are shown in FIGS. 5 and 6.

도 5에 나타난 바와 같이, LPS만 처리한 군에서는 NO가 과량 생성되었으며, 상기 LPS와 함께 본 발명의 민들레 열수추출물의 농도를 점차 증가하여 투여했을 경우에는 그 농도가 증가할수록 NO의 생성이 더욱 억제됨을 확인할 수 있었고, 도 6에 나타난 바와 같이, 이때의 세포생존율에는 전혀 변화가 없음을 확인하였다.As shown in FIG. 5, in the LPS-treated group, excess NO was generated, and when the concentration of the dandelion hot water extract of the present invention was gradually increased and administered together with the LPS, the production of NO was further inhibited as the concentration was increased. It was confirmed that, as shown in Figure 6, it was confirmed that there is no change in the cell viability at this time.

따라서, 본 발명의 민들레 열수추출물은 면역세포가 활성화되었을 때 세포생존율에는 변화를 일으키지 않으면서 NO의 생성을 농도 의존적으로 억제하고 있음을 알 수 있었다.Therefore, it was found that the dandelion hot water extract of the present invention inhibits NO production in a concentration-dependent manner without causing a change in cell viability when immune cells are activated.

실시예 5: 민들레 열수추출물에 의한 과산화수소에 의한 세포 손상 회복 Example 5 Recovery of Cell Damage by Hydrogen Peroxide by Dandelion Hot Water Extract

본 발명의 민들레 열수추출물이 산화적 스트레스에 의한 세포 손상을 회복시키는지 확인하기 위하여, 과산화수소를 사용하여 세포 손상을 유도했을 때 민들레 열수추출물의 효과를 측정하였다. In order to confirm whether the dandelion hot water extract of the present invention restores cell damage caused by oxidative stress, the effect of dandelion hot water extract was measured when the cell damage was induced using hydrogen peroxide.

구체적으로, RAW264.7 세포를 RPMI 배지를 이용하여 1×106 세포/㎖의 농도로 현탁하여 배양접시에 깐 다음, 5% CO2 배양기에서 37℃의 조건으로 배양하면서 민들레 열수추출물을 100, 500 및 1,000 ㎍/ml의 농도로 처리하고, 1시간 후에 세포 손상을 유발시키기 위하여 과산화수소 200 μM 및 500 μM을 처리한 후 다시 18시간 동안 배양하였다. 대조군으로는 민들레 열수추출물을 처리하지 않은 군 및 과 산화수소를 처리하지 않은 군을 사용하였다. 이후, 세포를 회수하여 세포생존율 측정에 이용하였으며, 세포생존율은 MTT 분석법에 따라 측정하여 그 결과를 도 7에 나타내었다. Specifically, the RAW264.7 cells were suspended in a concentration of 1 × 10 6 cells / ml using RPMI medium and placed in a culture dish, followed by culturing at 37 ° C. in a 5% CO 2 incubator to obtain 100, 100% of dandelion hot water extract. The cells were treated at concentrations of 500 and 1,000 μg / ml, and treated with 200 μM and 500 μM of hydrogen peroxide to induce cell damage after 1 hour and then incubated for another 18 hours. As a control group, the group without the dandelion hot water extract and the group without the hydrogen peroxide were used. Thereafter, cells were collected and used for measuring cell viability, and cell viability was measured according to the MTT assay, and the results are shown in FIG. 7.

도 7에 나타난 바와 같이, 과산화수소만 처리한 군에서는 세포 손상에 의한 세포 생존율 감소가 나타났으며, 본 발명의 민들레 열수추출물의 농도를 점차 증가하여 투여했을 경우에는 그 농도가 증가할수록 과산화수소에 의한 세포 생존율 감소가 더욱 회복됨을 확인하였다.As shown in FIG. 7, in the group treated with hydrogen peroxide only, the cell viability was decreased due to cell damage. When the concentration of dandelion hot water extract of the present invention was gradually increased and administered, the cells with hydrogen peroxide increased as the concentration increased. It was confirmed that the reduction in survival rate was further recovered.

따라서, 본 발명의 민들레 열수추출물은 산화적 스트레스에 의한 세포 손상을 방지하는 효과가 있음을 알 수 있었다.Therefore, the dandelion hot water extract of the present invention was found to have an effect of preventing cell damage by oxidative stress.

제제예 1: 민들레 열수추출물을 유효성분으로 함유하는 약제의 제조 Formulation Example 1 : Preparation of a medicament containing dandelion hot water extract as an active ingredient

<1-1> 정제의 제조<1-1> Preparation of Tablet

민들레 열수추출물 25 ㎎을 부형제 직타용 락토오스 26 ㎎과 아비셀 (미세결정 셀룰로오스) 3.5 ㎎, 붕해 보조제인 나트륨 전분 글리코네이드 1.5 ㎎ 및 결합제인 직타용 L-HPC (low-hydrosyprophylcellulose) 8 ㎎과 함께 U형 혼합기에 넣고 20분간 혼합하였다. 혼합이 완료된 후 활택제로서 마그네슘 스테아레이트 1 ㎎을 추가로 첨가하고 3분간 혼합하였다. 정량 시험과 항습도 시험을 거쳐 타정하고 필름 코팅하여 정제를 제조하였다.25 mg of dandelion hot water extract was U-type, with 26 mg of lactose for excipients and 3.5 mg of Avicel (microcrystalline cellulose), 1.5 mg of sodium starch glyconide as a disintegration aid, and 8 mg of low-hydrosyprophylcellulose (L-HPC) for binders. The mixture was put into a mixer and mixed for 20 minutes. After mixing was completed, 1 mg of magnesium stearate was further added as a lubricant and mixed for 3 minutes. Tablets were prepared by tableting and film coating after a quantitative test and a humidity test.

<1-2> 시럽제의 제조<1-2> Preparation of Syrup

민들레 열수추출물 2 g, 사카린 0.8 g 및 당 25.4 g을 온수 80 g에 용해시켰다. 상기 용액을 냉각시킨 후 글리세린 8.0 g, 향미료 0.04 g, 에탄올 4.0 g, 소르브산 0.4 g 및 적량의 증류수를 혼합한 다음, 물을 첨가하여 100 ㎖가 되도록 하였다.2 g of dandelion hot water extract, 0.8 g of saccharin and 25.4 g of sugar were dissolved in 80 g of warm water. After cooling the solution, 8.0 g of glycerin, 0.04 g of flavor, 4.0 g of ethanol, 0.4 g of sorbic acid, and an appropriate amount of distilled water were mixed, and then water was added to make 100 ml.

<1-3> 캡슐제의 제조<1-3> Preparation of Capsule

민들레 열수추출물 50 ㎎, 유당 50 ㎎, 전분 46.5 ㎎, 탈크 1 ㎎ 및 적량의 스테아린산 마그네슘을 혼합하고 이를 경질 젤라틴 캡슐에 충진함으로써 캡슐제를 제조하였다.A capsule was prepared by mixing dandelion hot water extract 50 mg, lactose 50 mg, starch 46.5 mg, talc 1 mg, and an appropriate amount of magnesium stearate and filling it into a hard gelatin capsule.

<1-4> 주사제의 제조<1-4> Preparation of Injection

민들레 열수추출물 1 g, 염화나트륨 0.6 g 및 아스코르브산 0.1 g을 증류수에 용해시켜서 최종 부피가 100 ㎖가 되도록 하였다. 상기 용액을 앰플에 충진하고 가열 멸균하였다.1 g of dandelion hot water extract, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to obtain a final volume of 100 ml. The solution was filled in ampoules and heat sterilized.

도 1은 민들레 열수추출물의 투여량에 따른 HO-1 효소 활성도의 측정 결과를 나타낸 것이다.Figure 1 shows the measurement results of HO-1 enzyme activity according to the dose of dandelion hot water extract.

도 2는 민들레 열수추출물 (TOWE)의 투여량에 따른 HO-1 단백질 생성 유도의 측정 결과를 나타낸 것이다.Figure 2 shows the measurement results of HO-1 protein production induction according to the dose of dandelion hot water extract (TOWE).

도 3은 민들레 열수추출물 (TOWE)의 투여량에 따른 HO-1의 mRNA 발현 유도를 나타낸 것이다.Figure 3 shows the induction of mRNA expression of HO-1 according to the dose of dandelion hot water extract (TOWE).

도 4는 민들레 열수추출물 (TOWE)의 투여량에 따른 iNOS의 단백질 발현 억제를 나타낸 것이다.Figure 4 shows the inhibition of protein expression of iNOS according to the dose of dandelion hot water extract (TOWE).

도 5 및 6은 민들레 열수추출물 (TOWE)의 투여량에 따른 NO 생성 억제와 세포 생존율을 나타낸 것이다.5 and 6 show NO production inhibition and cell viability according to the dose of dandelion hot water extract (TOWE).

도 7은 민들레 열수추출물 (TOWE)의 투여량에 따른 과산화수소에 의한 세포 손상 회복을 나타낸 것이다.Figure 7 shows the recovery of cell damage by hydrogen peroxide according to the dose of dandelion hot water extract (TOWE).

Claims (4)

민들레 열수추출물 (dandelion (Taraxacum offininale) water extract, TOWE)을 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물.Dandelion hot water extract (Dandelion ( Taraxacum offininale ) A composition for preventing or treating immune diseases containing water extract, TOWE) as an active ingredient. 제 1 항에 있어서, The method of claim 1, 상기 민들레 열수추출물이 헴옥시게나제-1 (heme oxygenase-1, HO-1)의 mRNA 및 단백질 발현을 촉진시키는 것을 특징으로 하는, 면역질환의 예방 또는 치료용 조성물.The dandelion hot water extract is characterized in that to promote the mRNA and protein expression of heme oxygenase-1 (heme oxygenase-1, HO-1), a composition for preventing or treating immune diseases. 제 1 항에 있어서, The method of claim 1, 상기 질환이 급성 및 만성 감염, 급성 및 만성 기관지염, 골관절염, 류마티스 관절염, 정맥동염, 위장염, 대장염, 방광염, 요도염, 피부염, 결막염, 심막염, 복막염, 활막염, 흉막염, 건염, 담낭염, 질염 및 포도막염으로 이루어진 군 중에서 선택되는 것임을 특징으로 하는, 면역질환의 예방 또는 치료용 조성물. These diseases include acute and chronic infections, acute and chronic bronchitis, osteoarthritis, rheumatoid arthritis, sinusitis, gastroenteritis, colitis, cystitis, urethritis, dermatitis, conjunctivitis, pericarditis, peritonitis, peritonitis, pleurisy, tendinitis, cholecystitis, vaginitis and uveitis It is selected from the group consisting of, composition for the prevention or treatment of immune diseases. 제 1 항의 민들레 열수추출물을 포함하는 면역질환의 예방용 식품 조성물.Claim 1 food composition for the prevention of immune diseases comprising dandelion hot water extract.
KR1020070106083A 2007-10-22 2007-10-22 Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient KR101307501B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070106083A KR101307501B1 (en) 2007-10-22 2007-10-22 Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070106083A KR101307501B1 (en) 2007-10-22 2007-10-22 Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient

Publications (2)

Publication Number Publication Date
KR20090040631A true KR20090040631A (en) 2009-04-27
KR101307501B1 KR101307501B1 (en) 2013-10-15

Family

ID=40763948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070106083A KR101307501B1 (en) 2007-10-22 2007-10-22 Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient

Country Status (1)

Country Link
KR (1) KR101307501B1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101040682B1 (en) * 2010-11-04 2011-06-10 김병주 The composition where the exemption force is strengthened and the composition water which follows in him
KR101428363B1 (en) * 2013-02-18 2014-08-07 김구환 The manufacturing method of Herbal composition improving Musculoskeletal inflammatory disease
CN108904722A (en) * 2018-09-25 2018-11-30 安徽兆龙食品有限公司 A kind of high-performance bio preparation suitable for acute gastroenteritis
KR20190019660A (en) * 2017-08-18 2019-02-27 대한민국(농촌진흥청장) A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion
CN118186038A (en) * 2024-02-07 2024-06-14 北京伍冠肽斗生物科技有限责任公司 Dandelion compound peptide, preparation method and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013880B (en) * 2014-04-22 2017-06-30 青岛市市立医院 It is a kind of to treat Chinese medicine composition of peritonitis and preparation method thereof
CN104383486A (en) * 2014-11-10 2015-03-04 黄结云 Medicament for treating bronchitis of children

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101040682B1 (en) * 2010-11-04 2011-06-10 김병주 The composition where the exemption force is strengthened and the composition water which follows in him
KR101428363B1 (en) * 2013-02-18 2014-08-07 김구환 The manufacturing method of Herbal composition improving Musculoskeletal inflammatory disease
KR20190019660A (en) * 2017-08-18 2019-02-27 대한민국(농촌진흥청장) A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion
CN108904722A (en) * 2018-09-25 2018-11-30 安徽兆龙食品有限公司 A kind of high-performance bio preparation suitable for acute gastroenteritis
CN118186038A (en) * 2024-02-07 2024-06-14 北京伍冠肽斗生物科技有限责任公司 Dandelion compound peptide, preparation method and application thereof

Also Published As

Publication number Publication date
KR101307501B1 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
KR101307501B1 (en) Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient
WO2009157712A2 (en) Crude drug composition for cartilage regeneration, pain suppression, and edema suppression
WO2007083858A1 (en) Composition comprising the extract of siegesbeckiae herba for preventing and treating arthritis and the use thereof
KR101209574B1 (en) Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing compound isolated from Youngia denticulata as an active ingredient
KR20040075135A (en) Composition comprising the extract of Saururus chinensis having anti-inflammatory activity
KR100900343B1 (en) A Composition comprising the extract of Aralia continentalis improving cytotoxicity and liver injury for preventing and treating of liver disease
KR100972167B1 (en) Composition for antioxidation and preventing or treating immune disease comprising Alaria esculenta extract as an active ingredient
KR100679853B1 (en) Composition comprising the extract of Ailanthus altissima for the prevention or treatment of asthma and allergic disease
KR20210002378A (en) Hepatoprotective composition containing pini pollen extract as effective component
KR101692889B1 (en) Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases
KR20120097080A (en) Composition comprising hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease
WO2019083264A1 (en) Composition for preventing, alleviating or treating liver diseases, containing fermented product of aged sprout ginseng extract as active ingredient
KR20150072660A (en) Hepatoprotective composition containing adenophora triphylla extract
KR101248378B1 (en) Pharmaceutical composition for arthritis treatment and prevention
KR20040033983A (en) Composition comprising the stem bark extract of Acanthopanax senticosus and liriodendrin therefrom having anti-inflammatory and antinociceptive activity
KR101059075B1 (en) Composition for the treatment and prevention of alcoholic liver disease containing non-leaflet extract
KR100547560B1 (en) Pharmaceutical composition comprising the extract of Kalopanax pictus, Pueraria thunbergiana and Rhus verniciflua having anti-inflammatory activity.
KR100765419B1 (en) Health care composition comprising saucerneol b isolated from saururus chinensis for the prevention and alleviation of inflammatory, allergy and asthma diseases
KR20100008220A (en) Composition for preventing and treating colon cancer containing extract of mushroom and herb medicine
KR100895500B1 (en) Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient
KR100547554B1 (en) A composition containing thawed bark, brownish, sumac extract having anti-inflammatory activity
KR20050084725A (en) Composition comprising an extract of anthriscus sylvesstris for prevention and treatment of inflammatory or allergy diseases
KR20150072659A (en) Hepatoprotective composition containing smilax china extract
KR20100136739A (en) Composition for antioxidation and preventing or treating immune disease comprising laminaria japonica extract as an active ingredient
KR100905387B1 (en) Composition comprising solvent extract of berberis koreana palibin having anti-inflammatory and immuno-modulatory activity

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160804

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170707

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee